Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism

NCT01268098 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT01268098
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01268098 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Dose-blinded Study to Investigate the Safety and Efficacy of NPSP558, a Recombinant Human Parathyroid Hormone [rhPTH(1-84)], at Fixed Doses of 25 µg and 50 µg for the Treatment of Adults With Hypoparathyroidism
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
February 9, 2011
Completion date
November 11, 2011
Enrollment
42 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hypoparathyroidism